Customers can now use HSA/FSA funds on eligible skincare and health products at Dermstore.com
NEW YORK, Aug. 4, 2025 /PRNewswire/ -- Online beauty retailer Dermstore, a...
Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.1 Results show that Susvimo’s immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States.
PHILADELPHIA, July 31, 2025 /PRNewswire/ -- FMC Corporation (NYSE: FMC), a leading global agricultural sciences company, today announced it has received registration for Fundatis®...
Maintains full year adjusted EBITDA and adjusted EPS guidance; announces sale of India commercial business
Second Quarter 2025 Highlights
Revenue of $1.05 billion, up 1...
CALGARY, AB, July 30, 2025 /PRNewswire/ - Canadian Pacific Kansas City (TSX: CP) (NYSE: CP) (CPKC) today announced its second-quarter results, including revenues of $3.7...
CALGARY, AB, July 30, 2025 /CNW/ - Canadian Pacific Kansas City (TSX: CP) (NYSE: CP) (CPKC) today announced its second-quarter results, including revenues of $3.7...
Second Quarter 2025 Financial Highlights
Revenue of $174 million increased 11% sequentiallyNet income before taxes of $19.4 million increased $14.4 million sequentiallyAdjusted EBITDA of $35.9...